Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 24, 2024
Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Evaxion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the EVX-V1 (CMV vaccine candidate) under a potential development and commercialization agreement.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 12, 2022
Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Evaxion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The EU Horizon 2020 Consortium
Deal Size : $0.9 million
Deal Type : Funding
ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme
Details : The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 03, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The EU Horizon 2020 Consortium
Deal Size : $0.9 million
Deal Type : Funding